---
title: "153 Series A Biotech Investors (Nov 2026)"
last_updated: "2026-11-07"
rows: "153"
free_rows: "25"
source: "SEC Form D filings and our own research"
canonical: "https://theinvestordatabase.com/lists/series-a-biotech-investors/"
---

# 153 Series A biotech investors

We list 153 Series A biotech investors as of November 2026: 60 have an SEC filing on file and 93 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The states with the most are California (21), New York (8) and Massachusetts (5).

- 153 investors
- 83 with a fund filing or dated deal in the last 12 months
- $90M median fund size on file (SEC Form D, 39 firms)
- 785 named decision-makers on file

## First 25 of 153 Series A biotech investors

| Investor | Type | HQ | Stages (our research) | Focus (our research) | Latest fund or deal | Fund size | Checked | Profile |
|---|---|---|---|---|---|---|---|---|
| Cambridge Innovation Capital | VC firm | Cambridge, United Kingdom | Seed, Series A, Growth | Biotech, Healthtech, AI, Fintech | New fund, Oct 2026 | £600M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/cambridge-innovation-capital/ |
| Felicis | VC firm | Menlo Park, CA | Seed, Series A | Biotech, AI, Developer Tools, Healthtech | New deal, Oct 2026 | $900M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/felicis/ |
| Angelor | VC firm | Lyon, France | Seed, Series A | Biotech, Healthtech, Medtech, Food and Beverage | New deal, Sep 2026 | €100M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/angelor/ |
| SHD Partners | VC firm | Dallas, TX | Seed, Series A | Biotech, Healthtech, Medtech | Portfolio news, Nov 2026 | $61M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/shd-partners/ |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | $2.8B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/hbm-partners-ag/ |
| Epidarex Capital | VC firm | Edinburgh, United Kingdom | Seed, Series A | Biotech, Healthtech, Medtech | Portfolio news, Jul 2026 | $17M (SEC Form ADV) | 2026-11-04 | https://theinvestordatabase.com/investors/epidarex-capital/ |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Biotech, Medtech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/andera-partners/ |
| Biovance Capital | VC firm | Lisbon, Portugal | Seed, Series A | Biotech, Healthtech | New deal, Sep 2026 | €60M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/biovance-capital-partners-sociedade-de-capital-de-risco-s-a/ |
| Claris Ventures | VC firm | Turin, Italy | Pre-seed, Seed, Series A | Biotech, Healthtech | New fund, Oct 2026 | €190M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/claris-ventures-sgr/ |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Biotech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/bgf/ |
| Outlier Ventures | VC firm | United Kingdom | Pre-seed, Seed, Series A, Growth | Biotech, AI, Robotics, Fintech | New deal, Oct 2026 | $500M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/outlier-ventures/ |
| Hadean Ventures | VC firm | Norway | Seed, Series A, Series B | Biotech, Healthtech, Medtech | New deal, Sep 2026 | €230M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/hadean-ventures-as/ |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/madrona/ |
| 819 Capital Partners | VC firm | Deventer, Netherlands | Seed, Series A, Growth | Biotech, Healthtech, Medtech, Generalist | Portfolio news, Sep 2026 | €100M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/819-capital-partners/ |
| Bison Ventures | VC firm | San Francisco, CA | Pre-seed, Seed, Series A, Series B | Biotech, AI, Healthtech, Energy | New fund, Oct 2026 | $160M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/bison-ventures/ |
| Sofinnova Partners | VC firm | France (London office) | Seed, Series A, Series B, Growth | Biotech, Healthtech, Fintech, Agritech | New fund, Nov 2025 | €4.0B (own site) | 2026-11-05 | https://theinvestordatabase.com/investors/sofinnova-partners/ |
| Magnetic Ventures | VC firm | Miami Beach, FL | Seed, Series A | Biotech, AI, Healthtech, Edtech | New fund, Mar 2026 | $100M (SEC Form D, 2022) | 2026-11-04 | https://theinvestordatabase.com/investors/magnetic-ventures/ |
| DeepWork Capital | VC firm | Orlando, FL | Seed, Series A | Biotech, Healthtech, Fintech, AI | New deal, Jun 2026 | $100M (SEC Form D, 2023) | 2026-11-05 | https://theinvestordatabase.com/investors/deepwork-capital/ |
| Kapor Capital | VC firm | Oakland, CA | Pre-seed, Seed, Series A | Biotech, Edtech, Fintech, Healthtech | New deal, Jun 2026 | $125M (SEC Form D, 2021) | 2026-11-05 | https://theinvestordatabase.com/investors/kapor-capital/ |
| Cornucopian Capital | VC firm | Montclair, NJ | Pre-seed, Seed, Series A, Series B | Biotech, Healthtech, AI, Medtech | New fund, Aug 2026 | $12M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/cornucopian-capital/ |
| Archangels | Angel network | Edinburgh, United Kingdom | Pre-seed, Seed, Series A, Growth | Biotech, Media, Deep Tech, Healthtech | Portfolio news, Nov 2026 | £10M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/archangels/ |
| Union Square Ventures | VC firm | New York, NY | Seed, Series A | Biotech, AI, Generalist, Robotics | New deal, Oct 2026 | $3M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/union-square-ventures/ |
| Draper Associates | VC firm | San Mateo, CA | Pre-seed, Seed, Series A | Biotech, AI, Fintech, Healthtech | New fund, Oct 2026 | $301M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/draper-associates/ |
| Wellington Partners | VC firm | Munich, Germany | Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, May 2026 | €210M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/wellington-partners/ |
| MGP Venture Fund III | VC firm | Nashville, TN | Series A | Biotech, Healthtech, Agritech, Energy | Portfolio news, Jul 2025 | $150M (SEC Form D, 2021) | 2026-11-05 | https://theinvestordatabase.com/investors/mgp-venture-fund-iii/ |

You are seeing 25 of 153. The full list adds 128 more investors and 785 named decision-makers.

Get all 153 investors and 785 named contacts, $49, one-time: https://theinvestordatabase.com/buy/list/series-a-biotech-investors
This page: https://theinvestordatabase.com/lists/series-a-biotech-investors/

## Method and limits
- Source: 60 of the 153 rows carry an SEC filing (Form D or Form ADV). All 153 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule: Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at Series A.
- Order: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when Series A is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Fill rates: Of 153 rows: stage 153, sector 153, fund size 91, website 153. In the paid file: named decision-makers on 145 rows, firm email on 86, LinkedIn page on 110, check size on 46.

## Questions
### How many Series A biotech investors are there?
We list 153 as of November 2026. 83 of the 153 have a fund filing or a dated deal in the last 12 months.

### Which Series A biotech investors raised a new fund in the last 12 months?
23 of the 153 have a fund filing dated in the last 12 months. The most recent on this list are Draper Associates (Oct 2026), Bison Ventures (Oct 2026) and Overlap Holdings (Oct 2026).

### What is the typical fund size of Series A biotech investors?
The median fund size on file for this list is $90M, across the 39 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 114 do not disclose a size there.

### How do I contact Series A biotech investors?
The paid file holds 785 named decision-makers across 145 of these 153 and a firm email for 86. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.

### Where does the data on Series A biotech investors come from?
60 of the 153 rows have an SEC filing on file (Form D or Form ADV) and 93 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.